Labcorp Q4 revenue $3.52B (+5.6% YoY), adj EPS $4.07 beat; guides FY26 adj EPS $17.55-18.25

LABCORP HOLDINGS INC.

2025-FY EPS reported $10.46 revenue$13,951,700,000

Q4 revenue $3.52B (up 5.6% YoY, organic 3.8%); diluted EPS $1.98; adjusted EPS $4.07 vs $3.45.
Full-year 2025 revenue $13.95B (+7.2% YoY); adj EPS $16.44 (+12.8% YoY); free cash flow $1.21B.
2026 guidance: revenue $14.61-14.79B (midpoint +5.4%), adj EPS $17.55-18.25 (midpoint +8.9%), FCF $1.24-1.36B.
Diagnostics revenue $2.73B (+5.5%); adj op margin 15.4% (up 150 bps). Biopharma Central Labs grew 11.1%.
Repurchased $450M stock in 2025; declared $0.72/share dividend payable Mar 12, 2026; signed 13 lab partnership deals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.